Contact
searchSearch
HMP Global

Psychedelics News

psilocybin mushrooms in a beaker
Psychedelics Update
Compass Pathways Submits COMP360 Psilocybin Application for Treatment-Resistant Depression
11/09/2026
Maria Mantas
Compass Pathways has completed submission of a New Drug Application for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression.
Compass Pathways has completed submission of a New Drug Application for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression.
Compass Pathways has completed...
11/09/2026
Psych Congress Network
A lab tech handles psilocybin mushrooms in a research lab
Research Summary
Psilocybin Linked to Lower Inflammatory Markers in Parkinson Disease
11/09/2026
Brionna Mendoza
Psilocybin administration was associated with reductions in markers of systemic inflammation and mitochondrial stress among people with PD and mood dysfunction, according to a research letter published in JAMA Psychiatry.
Psilocybin administration was associated with reductions in markers of systemic inflammation and mitochondrial stress among people with PD and mood dysfunction, according to a research letter published in JAMA Psychiatry.
Psilocybin administration was...
11/09/2026
Psych Congress Network
intranasal spray bottles
Research Summary
Mebufotenin Shows Rapid Antidepressant Effects in Phase 2b Trial
11/02/2026
Brionna Mendoza
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of...
11/02/2026
Psych Congress Network
fda building sign
News
FDA Grants DT120 Second Breakthrough Designation, Now for MDD
09/09/2026
Brionna Mendoza
The US FDA has granted Breakthrough Therapy designation to DT120, an orally disintegrating lysergide tablet, for the treatment of MDD.
The US FDA has granted Breakthrough Therapy designation to DT120, an orally disintegrating lysergide tablet, for the treatment of MDD.
The US FDA has granted...
09/09/2026
Psych Congress Network
psilocybin
Research Summary
Oregon Psilocybin Program Shows Mental Health Improvements, Few Serious Reactions
08/20/2026
Maria Mantas
Participants in Oregon’s state-regulated psilocybin program reported improvements in depression, anxiety, PTSD symptoms, mental well-being, and life satisfaction over 3 months.
Participants in Oregon’s state-regulated psilocybin program reported improvements in depression, anxiety, PTSD symptoms, mental well-being, and life satisfaction over 3 months.
Participants in Oregon’s...
08/20/2026
Psych Congress Network
Rakesh Jain, MD, MPH
Rapid Reaction
Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health
07/16/2026
Rakesh Jain, MD, MPH, RD; Maria Mantas
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds...
07/16/2026
Psych Congress Network
A patient sits across from a doctor who has a clipboard and is filling out a phone
Research Summary
Single-Dose LSD Formulation Hits Primary Endpoint in Phase 3 MDD Trial
06/29/2026
Brionna Mendoza
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation...
06/29/2026
Psych Congress Network
A clinician in the lab pulls a psilocybin mushroom from a bag using tweezers major depressive disorder mdd treatment
News
Single-Dose Psilocybin Rapidly Improves MDD Symptoms, RCT Finds
05/19/2026
Brionna Mendoza
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was...
05/19/2026
Psych Congress Network
A patient receives psychedelic-assisted therapy
News
Presidential Executive Order Seeks to Expand Psychedelic Access for Tough-To-Treat Mental Illnesses
04/29/2026
Brionna Mendoza
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed...
04/29/2026
Psych Congress Network
a man with depression looks out a window major depressive disorder
Research Summary
Psilocybin Produces Mixed Outcomes in Phase 2b MDD Study
04/01/2026
Brionna Mendoza
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical...
04/01/2026
Psych Congress Network

NEW FROM PSYCH CONGRESS NP INSTITUTE

Michael Asbach and Arwen Podesta
Clinical Pearls
Making Lifestyle Interventions Practical and Accessible in MDD Care
10/29/2026
Michael Asbach, DMSc, PA-C; Arwen Podesta, MD
Arwen Podesta, MD, DFAPA, Psych Congress Steering Committee Member, and Mike Asbach, DMSc, PA-C, Co-Chair, Psych Congress PA Institute, discuss practical strategies for incorporating nutrition and exercise recommendations into psychiatric...
Arwen Podesta, MD, DFAPA, Psych Congress Steering Committee Member, and Mike Asbach, DMSc, PA-C, Co-Chair, Psych Congress PA Institute, discuss practical strategies for incorporating nutrition and exercise recommendations into psychiatric...
Arwen Podesta, MD, DFAPA, Psych...
10/29/2026
Psych Congress NP Institute
Michael Asbach and Arwen Podesta
Clinical Pearls
Addressing Lifestyle Factors in Major Depressive Disorder
10/23/2026
Michael Asbach, DMSc, PA-C; Arwen Podesta, MD
How can clinicians incorporate lifestyle interventions into major depressive disorder (MDD) treatment alongside pharmacotherapy?
How can clinicians incorporate lifestyle interventions into major depressive disorder (MDD) treatment alongside pharmacotherapy?
How can clinicians incorporate...
10/23/2026
Psych Congress NP Institute
Kristian Dambrino, DNP, PMHNP-BC
Clinical Pearls
Exploring the Role of Dual-Mechanism and Multimodal Antidepressants in MDD Treatment
10/13/2026
Kristian Dambrino, DNP, APRN, MSN
Kristian Dambrino, DNP, PMHNP-BC, explores the role that dual-mechanism and multimodal medications may play in individualized major depressive disorder (MDD) care.
Kristian Dambrino, DNP, PMHNP-BC, explores the role that dual-mechanism and multimodal medications may play in individualized major depressive disorder (MDD) care.
Kristian Dambrino, DNP,...
10/13/2026
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use